Tempus, a Chicago-based company, has reached a new milestone in compiling clinical data. In the wake of announcing a soaring amount of $110 million in Series E Funding, the company has launched a mobile app that allows physicians to access clinical and genomic data called Tempus Labs. It is currently available on smart stores, Apple and Google Play. keeping up to date with the trend of information technology, Tempus has sought to leverage its niche in data collection and analysis.
What exactly does the app feature? In terms of the patient information, it provides a detailed overview of the patient’s clinical history. In addition, it includes therapy options potentially required by the patient and informs of his eligibility for any clinical trials.
In terms of assays, the app grants access to physicians who order either CLIA or CAP Tempus. These are validated assays that analyzes 595 genes ( xT) and 1714 genes (xO; while xE analyzes the whole exome.
With the creation of this app, the intention is to build convenience for physicians to access the Tempus platform from wherever they are. The instant acquiring of data immediately at their fingertips is what makes the App primarily beneficial.
The development of this app the was directly based on the discussions with physicians. It incorporated their feedback on time-consuming schedules that make working on a computer challenging. Fukushima has added that the release of this app has enabled doctors to access information with more convenience than ever before. The ultimate goal has not only resulted in creating ease but also in improving the physician’s decisions in prescribing better treatments.
With regards to its announcement of The Series E round Funding, investments poured in from Baillie Gifford, Revolution Growth, New Enterprise Associates and other investors.
The investment secured is planned to be used in expanding operations that will cater to new therapeutic areas like cardiovascular disease or neurological disorders.
Tempus is founded by Eric Leftofsky who serves in the capacity of a chairperson and a co-founder. Eric Lefkofsky, known for founding Group, has sought to create a library that features molecular and clinical data. He has established an operating system which facilitates data accessions under the name of Tempus O. This system is an amenity that structures/organizes and annotates clinical data. It was birthed last December and is set to make waves in the medical industry of data collection.